Mon panier

PVRIG

PVRIG Informations sur la molécule

Nom anglaisTransmembrane protein PVRIGNombre de médicaments commercialisés0
Nombre de médicaments cliniques7Alias de la ciblePVRIG,PVR Related Immunoglobulin Domain Containing,CD112 Receptor,Poliovirus Receptor-Related Immunoglobulin Domain-Containing Protein,Poliovirus Receptor Related Immunoglobulin Domain Containing,Nectin-2 Receptor,C7orf15,CD112R,Transmembrane Protein PVRIG,MGC2463
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisTransmembrane protein PVRIG
Alias de la ciblePVRIG,PVR Related Immunoglobulin Domain Containing,CD112 Receptor,Poliovirus Receptor-Related Immunoglobulin Domain-Containing Protein,Poliovirus Receptor Related Immunoglobulin Domain Containing,Nectin-2 Receptor,C7orf15,CD112R,Transmembrane Protein PVRIG,MGC2463
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques7
Phase de R&D la plus avancéePhase 2 Clinical

PVRIG Liste de produits

  • Attribut

    Protein (11)

  • Bibliothèque de produits

    En ligne (11)

  • Espèces

    Human (5)Mouse (4)Cynomolgus (2)

  • Étiquette

    His Tag (4)Fc Tag (3)His Tag & Avi Tag (2)Mouse IgG Fc Tag (1)Fc Tag & Avi Tag (1)

  • Marqueur

    Unconjugated (8)Biotin-labeled (3)

PVRIGContexte de la molécule

Human PVRIG (poliovirus receptor related immunoglobulin domain-containing protein), also known as CD112 receptor (CD112R), is an approximately 34 kDa single transmembrane protein in the poliovirus receptor-like protein (PVR) family. The CD112R gene encodes a putative single transmembrane protein, which is composed of a single extracellular IgV domain, one transmembrane domain, and a long intracellular domain. Notably, the intracellular domain of phatases. The extracellular domain sequence of human and mouse CD112R have 65.3% similarity. CD112R may act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals.

PVRIGAlias de la molécule

C7orf15,C7orf15MGC138295,CD112R,MGC104322,MGC138297,MGC2463,PVRIG,CD112 receptor

Plateforme de commerce de projets d'anticorps

Nom du projetPhase du projetType de moléculeSource de moléculeDomain thérapeutiqueIndication
TIGIT&PVRIG BsAb - 01PCCMonoclonalHumanized MouseSolid TumorSolid tumor

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
COM-701COM-701Phase 2 ClinicalCompugen LtdBreast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
PM-1009PM1009Phase 2 ClinicalCarcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours
Details
SIM-0348SIM-0348Phase 1 ClinicalSimcere Pharmaceutical Group LtdNeoplasms; Solid tumours
Details
GSK-4381562SRF-813; GSK-4381562; GSK-4381562A; GSK4381562A; GSK’562Phase 1 ClinicalSurface Oncology IncNeoplasms; Solid tumours
Details
NM1FNM1F; TGI-2Phase 1 ClinicalHefei TG ImmunoPharma Co LtdColorectal Neoplasms; Melanoma; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
SHR-2002SHR-2002Phase 1 ClinicalShanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co LtdNeoplasms
Details
JS-009JS009; TAB009; JS-009Phase 1 ClinicalShanghai Junshi Biosciences Co LtdNeoplasms; Solid tumours
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques